Is it Time to Dump CytoDyn Inc (CYDY) Stock After it Is Higher By 45.00% in a Week?

The market has been high on CytoDyn Inc (CYDY) stock recently. CYDY gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CytoDyn Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CYDY!

See Full CYDY Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CYDY Stock Today?

CytoDyn Inc (CYDY) stock is unmoved -0.02% while the S&P 500 has gained 0.57% as of 12:32 PM on Thursday, Jul 21. CYDY is unchanged $0.00 from the previous closing price of $0.59 on volume of 3,039,602 shares. Over the past year the S&P 500 is down -7.88% while CYDY is down -69.31%. CYDY lost -$0.23 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for CytoDyn Inc click here.

More About CytoDyn Inc

CytoDyn Inc is a US-based clinical-stage biotechnology company which focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The lead product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes on exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer. Click Here to get the full Stock Report for CytoDyn Inc stock.